These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 39065204)

  • 1. Tixagevimab/Cilgavimab as SARS-CoV-2 Pre-Exposure Prophylaxis in Lung Transplant Recipients during the Omicron Wave: A Real-World Monocentric Experience.
    Cona A; Tavelli A; Agrenzano S; Hafeez N; Scianna G; Maria A; Marino F; Cruz E; Giorgio MD; Osorio E; Cucinella G; Luca A; Provenzani A; Vitulo P; Bertani A; Grossi PA; Mularoni A
    Microorganisms; 2024 Jul; 12(7):. PubMed ID: 39065204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-exposure Prophylaxis with Tixagevimab-cilgavimab did not Reduce Severity of COVID-19 in Lung Transplant Recipients with Breakthrough Infection.
    Sindu D; Razia D; Grief K; Cherrier L; Omar A; Walia R; Tokman S
    Transplant Direct; 2023 Jun; 9(6):e1485. PubMed ID: 37197016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world experience of tixagevimab-cilgavimab pre-exposure prophylaxis in orthotopic heart transplant recipients.
    Ordaya EE; Higgins EM; Vergidis P; Razonable RR; Beam E
    Transpl Infect Dis; 2023 Jun; 25(3):e14040. PubMed ID: 36847413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the post hoc effectiveness of tixagevimab-cilgavimab for prevention of SARS-CoV-2 infections in solid organ transplant recipients.
    Jordan SC; Joung SY; Wang M; Tran TA; Bravo M; Masoom H; Chang C; Mendez M; Sun N; Patel J; Kittleson M; Frias E; Prostko JC; Ebinger JE; Cheng S; Sobhani K
    Transpl Infect Dis; 2024 Feb; 26(1):e14182. PubMed ID: 37885435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single-center review of pre-exposure prophylaxis with tixagevimab-cilgavimab in solid organ transplant recipients.
    Morado F; Davoudi R; Kawewat-Ho P; Nanda N; Cartus R; Shaikh SA
    Transpl Infect Dis; 2023 Aug; 25(4):e14086. PubMed ID: 37314092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prevention of COVID-19 in High-Risk Patients Using Tixagevimab-Cilgavimab (Evusheld): Real-World Experience at a Large Academic Center.
    Al-Obaidi MM; Gungor AB; Kurtin SE; Mathias AE; Tanriover B; Zangeneh TT
    Am J Med; 2023 Jan; 136(1):96-99. PubMed ID: 36181789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave.
    Al Jurdi A; Morena L; Cote M; Bethea E; Azzi J; Riella LV
    Am J Transplant; 2022 Dec; 22(12):3130-3136. PubMed ID: 35727916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tixagevimab/cilgavimab prophylaxis against COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis.
    Khorramnia S; Navidi Z; Orandi A; Iravani MM; Orandi A; Malekabad ES; Moghadam SHP
    Clin Transplant Res; 2024 Jun; 38(2):136-144. PubMed ID: 38904088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tixagevimab/cilgavimab for the prevention of COVID-19 in solid organ transplant recipients.
    Eribes E; Votruba C; Tinkham T; Huang A; Ilges D; Kunze K; Hudson M
    Clin Transplant; 2024 Feb; 38(2):e15261. PubMed ID: 38375915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving impact of the COVID-19 pandemic on lung transplant recipients: A single-center experience.
    Sindu D; Razia D; Bay C; Padiyar J; Grief K; Buddhdev B; Arjuna A; Abdelrazek H; Mohamed H; McAnally K; Omar A; Walia R; Schaheen L; Tokman S
    J Heart Lung Transplant; 2024 Mar; 43(3):442-452. PubMed ID: 37852512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 Outcomes in Lung Transplant Recipients Following Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab During the Omicron BA.5 Surge: A Single Center Analysis.
    Demolder S; Schaevers V; Lagrou K; De Munter P; Beeckmans H; Verleden GM; Godinas L; Dupont LJ; Van Bleyenbergh P; Lorent N; Vos R
    Transpl Int; 2024; 37():12061. PubMed ID: 38328617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Anti-COVID-19 Vaccination and Pre-Exposure Prophylaxis with Tixagevimab-Cilgavimab in Kidney and Liver Transplant Recipients.
    Angelico R; Romano F; Coppola L; Materazzo M; Pedini D; Santicchia MS; Cacciola R; Toti L; Sarmati L; Tisone G
    Medicina (Kaunas); 2023 Nov; 59(12):. PubMed ID: 38138204
    [No Abstract]   [Full Text] [Related]  

  • 13. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.
    Hirsch C; Park YS; Piechotta V; Chai KL; Estcourt LJ; Monsef I; Salomon S; Wood EM; So-Osman C; McQuilten Z; Spinner CD; Malin JJ; Stegemann M; Skoetz N; Kreuzberger N
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD014945. PubMed ID: 35713300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tixagevimab-Cilgavimab Decreases the Rate of SARS-CoV-2 Infection Among Solid Organ Transplant Recipients.
    Sanayei AM; Montalvan A; Faria I; Ochalla J; Pavlakis M; Blair BM; Alonso CD; Curry M; Saberi B
    Transplant Proc; 2023 Oct; 55(8):1784-1792. PubMed ID: 37661468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis.
    Ordaya EE; Vergidis P; Razonable RR; Yao JD; Beam E
    J Clin Virol; 2023 Mar; 160():105382. PubMed ID: 36731147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients.
    Lombardi A; Viero G; Villa S; Biscarini S; Palomba E; Azzarà C; Iannotti N; Mariani B; Genovese C; Tomasello M; Tonizzo A; Fava M; Valzano AG; Morlacchi LC; Donato MF; Castellano G; Cassin R; Carrabba M; Muscatello A; Gori A; Bandera A
    Biomedicines; 2023 May; 11(6):. PubMed ID: 37371635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of pre-exposure prophylaxis to prevent SARS-CoV-2 infection after lung transplantation: a two center cohort study during the omicron era.
    Gottlieb J; Simon S; Barton J; Barnikel M; Bachmann M; Klingenberg MS; Veit T; Kneidinger N
    Infection; 2023 Oct; 51(5):1481-1489. PubMed ID: 36929650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of tixagevimab/cilgavimab for pre-exposure prophylaxis during the China Omicron outbreak.
    You J; Tian J; Wu H; Kang W; Wen J; Xu H; Shi W; Wang Z; Wei H; Du Y; Li X; Mu G; Zhou M; Gu Z; Qu J
    Expert Rev Anti Infect Ther; 2023; 21(12):1365-1371. PubMed ID: 37855094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients.
    Nguyen Y; Flahault A; Chavarot N; Melenotte C; Cheminant M; Deschamps P; Carlier N; Lafont E; Thomas M; Flamarion E; Lebeaux D; Charlier C; Rachline A; Guérin C; Ratiney R; Touchard J; Péré H; Rozenberg F; Lanternier F; Arlet JB; Avouac J; Boussaud V; Guillemain R; Vignon M; Thervet E; Scemla A; Weiss L; Mouthon L;
    Clin Microbiol Infect; 2022 Dec; 28(12):1654.e1-1654.e4. PubMed ID: 35926762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tixagevimab/cilgavimab for preventing COVID-19 during the Omicron surge: retrospective analysis of National Veterans Health Administration electronic data.
    Young-Xu Y; Epstein L; Marconi VC; Davey V; Korves C; Zwain G; Smith J; Cunningham F; Bonomo RA; Ginde AA
    mBio; 2023 Aug; 14(4):e0102423. PubMed ID: 37535398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.